Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy

Lisa A. Cavacini, Mark Duval, Ajay Patil, Charles Wood, Kenneth H. Mayer, Ruth M. Ruprecht, Marshall R. Posner

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The identification of broadly reactive and cross-clade neutralizing antibodies will facilitate the development of a more universally effective vaccine for human immunodeficiency virus (HIV). Antibodies in sera from individuals infected with Clade B HIV bind native primary viral isolates, and virus binding correlates with neutralization and stable clinical disease. In this study, we quantified cross-clade antibody reactivity and neutralization by Clades B and C sera. Primary viral isolates were captured by serum IgG bound to anti-human IgG and quantitated as p24 released by lysis of captured virus. Neutralization was determined using PHA-stimulated PBMC. Clade B antibodies reacted more frequently with Clade B R5 virus, but positive sera captured quantitatively more X4 virus than R5 and R5X4 virus. Clade B sera reacted less frequently and captured less Clade C virus than Clade B virus. Antibodies in Clade C sera captured Clades B and C isolates with equal frequency and quantity. There was no difference in neutralization of Clade B virus by either group of sera; however, Clade C sera neutralized Clade C virus, whereas Clade B sera were ineffective against Clade C virus. Thus, there are distinct differences in cross-clade reactivity of and neutralization by antibodies induced in response to Clade C infection compared to Clade B infection. Understanding antibody responses to native virions after Clade C infection and cross clade antibody behavior has implications for understanding pathogenesis and vaccine development.

Original languageEnglish (US)
Pages (from-to)146-152
Number of pages7
JournalJournal of Medical Virology
Volume76
Issue number2
DOIs
StatePublished - Jun 1 2005

Fingerprint

Active Immunotherapy
Passive Immunization
HIV-1
Cercopithecine Herpesvirus 1
Serum
Viruses
Antibodies
Vaccines
HIV
Virus Attachment
Cross Infection
Infection
Neutralizing Antibodies
Virion
Antibody Formation
Immunoglobulin G

Keywords

  • Cross-clade
  • Human immunodeficiency virus
  • Neutralization
  • Serum antibody

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera : Implications for active and passive immunotherapy. / Cavacini, Lisa A.; Duval, Mark; Patil, Ajay; Wood, Charles; Mayer, Kenneth H.; Ruprecht, Ruth M.; Posner, Marshall R.

In: Journal of Medical Virology, Vol. 76, No. 2, 01.06.2005, p. 146-152.

Research output: Contribution to journalArticle

Cavacini, Lisa A. ; Duval, Mark ; Patil, Ajay ; Wood, Charles ; Mayer, Kenneth H. ; Ruprecht, Ruth M. ; Posner, Marshall R. / Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera : Implications for active and passive immunotherapy. In: Journal of Medical Virology. 2005 ; Vol. 76, No. 2. pp. 146-152.
@article{deec7aff0780423c9c73dc7e63569d98,
title = "Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy",
abstract = "The identification of broadly reactive and cross-clade neutralizing antibodies will facilitate the development of a more universally effective vaccine for human immunodeficiency virus (HIV). Antibodies in sera from individuals infected with Clade B HIV bind native primary viral isolates, and virus binding correlates with neutralization and stable clinical disease. In this study, we quantified cross-clade antibody reactivity and neutralization by Clades B and C sera. Primary viral isolates were captured by serum IgG bound to anti-human IgG and quantitated as p24 released by lysis of captured virus. Neutralization was determined using PHA-stimulated PBMC. Clade B antibodies reacted more frequently with Clade B R5 virus, but positive sera captured quantitatively more X4 virus than R5 and R5X4 virus. Clade B sera reacted less frequently and captured less Clade C virus than Clade B virus. Antibodies in Clade C sera captured Clades B and C isolates with equal frequency and quantity. There was no difference in neutralization of Clade B virus by either group of sera; however, Clade C sera neutralized Clade C virus, whereas Clade B sera were ineffective against Clade C virus. Thus, there are distinct differences in cross-clade reactivity of and neutralization by antibodies induced in response to Clade C infection compared to Clade B infection. Understanding antibody responses to native virions after Clade C infection and cross clade antibody behavior has implications for understanding pathogenesis and vaccine development.",
keywords = "Cross-clade, Human immunodeficiency virus, Neutralization, Serum antibody",
author = "Cavacini, {Lisa A.} and Mark Duval and Ajay Patil and Charles Wood and Mayer, {Kenneth H.} and Ruprecht, {Ruth M.} and Posner, {Marshall R.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1002/jmv.20339",
language = "English (US)",
volume = "76",
pages = "146--152",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera

T2 - Implications for active and passive immunotherapy

AU - Cavacini, Lisa A.

AU - Duval, Mark

AU - Patil, Ajay

AU - Wood, Charles

AU - Mayer, Kenneth H.

AU - Ruprecht, Ruth M.

AU - Posner, Marshall R.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - The identification of broadly reactive and cross-clade neutralizing antibodies will facilitate the development of a more universally effective vaccine for human immunodeficiency virus (HIV). Antibodies in sera from individuals infected with Clade B HIV bind native primary viral isolates, and virus binding correlates with neutralization and stable clinical disease. In this study, we quantified cross-clade antibody reactivity and neutralization by Clades B and C sera. Primary viral isolates were captured by serum IgG bound to anti-human IgG and quantitated as p24 released by lysis of captured virus. Neutralization was determined using PHA-stimulated PBMC. Clade B antibodies reacted more frequently with Clade B R5 virus, but positive sera captured quantitatively more X4 virus than R5 and R5X4 virus. Clade B sera reacted less frequently and captured less Clade C virus than Clade B virus. Antibodies in Clade C sera captured Clades B and C isolates with equal frequency and quantity. There was no difference in neutralization of Clade B virus by either group of sera; however, Clade C sera neutralized Clade C virus, whereas Clade B sera were ineffective against Clade C virus. Thus, there are distinct differences in cross-clade reactivity of and neutralization by antibodies induced in response to Clade C infection compared to Clade B infection. Understanding antibody responses to native virions after Clade C infection and cross clade antibody behavior has implications for understanding pathogenesis and vaccine development.

AB - The identification of broadly reactive and cross-clade neutralizing antibodies will facilitate the development of a more universally effective vaccine for human immunodeficiency virus (HIV). Antibodies in sera from individuals infected with Clade B HIV bind native primary viral isolates, and virus binding correlates with neutralization and stable clinical disease. In this study, we quantified cross-clade antibody reactivity and neutralization by Clades B and C sera. Primary viral isolates were captured by serum IgG bound to anti-human IgG and quantitated as p24 released by lysis of captured virus. Neutralization was determined using PHA-stimulated PBMC. Clade B antibodies reacted more frequently with Clade B R5 virus, but positive sera captured quantitatively more X4 virus than R5 and R5X4 virus. Clade B sera reacted less frequently and captured less Clade C virus than Clade B virus. Antibodies in Clade C sera captured Clades B and C isolates with equal frequency and quantity. There was no difference in neutralization of Clade B virus by either group of sera; however, Clade C sera neutralized Clade C virus, whereas Clade B sera were ineffective against Clade C virus. Thus, there are distinct differences in cross-clade reactivity of and neutralization by antibodies induced in response to Clade C infection compared to Clade B infection. Understanding antibody responses to native virions after Clade C infection and cross clade antibody behavior has implications for understanding pathogenesis and vaccine development.

KW - Cross-clade

KW - Human immunodeficiency virus

KW - Neutralization

KW - Serum antibody

UR - http://www.scopus.com/inward/record.url?scp=17844398956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844398956&partnerID=8YFLogxK

U2 - 10.1002/jmv.20339

DO - 10.1002/jmv.20339

M3 - Article

C2 - 15834877

AN - SCOPUS:17844398956

VL - 76

SP - 146

EP - 152

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 2

ER -